Deepak Nitrite (DEEPAKNTR) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
2 Feb, 2026Executive summary
Q1 FY25 consolidated revenue rose 21%-22.5% year-over-year to ₹2,186 crore, with EBITDA up 36% to ₹328 crore and PAT up 35% to ₹203 crore, despite global headwinds and Chinese inventory destocking.
PAT margin improved to 9%-9.3% year-over-year.
Expansion plans include INR 2,000 crore in projects nearing completion and a total investment pipeline of INR 14,000 crore over four years.
Strategic focus on domestic and international markets, leveraging India's consumption growth and government support.
Early signs of volume recovery and improved customer sentiment, with meaningful recovery expected from Q3 onwards.
Financial highlights
Q1 FY25 consolidated revenue reached ₹2,186 crore, up 21% year-over-year; EBITDA grew 36% to ₹328 crore, with margin at 15%.
PAT increased 35% year-over-year to ₹203 crore; EPS rose to ₹14.85 from ₹10.99.
Domestic revenue at ₹1,786 crore (82%); export revenue at ₹399 crore (18%).
Insurance claim of ₹127 crore from a fire incident was fully received during the quarter.
Net debt negative position, with annual cash generation around ₹1,000 crore and net worth of ₹5,000 crore.
Outlook and guidance
Multiple projects, including new acid, MIBK/MIBC, hydrogenation plants, and a world-class R&D center, are scheduled for commissioning in FY25.
Management anticipates double-digit industry growth, with demand recovery expected in H2 FY25 as Chinese destocking concludes.
Backward integration and new product launches expected to drive future growth.
Short-term guidance maintained for meaningful recovery starting later in Q3 FY25.
Strategy focuses on value-added downstream products and sustainability initiatives.
Latest events from Deepak Nitrite
- Q3 FY26 saw 3% revenue growth, higher EBITDA, and margin resilience amid global headwinds.DEEPAKNTR
Q3 25/2613 Feb 2026 - H1 FY25 revenue and profit rose on phenolics strength and major polycarbonate investment.DEEPAKNTR
Q2 202514 Jan 2026 - Q3 FY25 profit and revenue fell, but margin recovery is expected as new projects ramp up.DEEPAKNTR
Q3 202516 Dec 2025 - Revenue and profit fell, but phenolics and expansion projects support future growth.DEEPAKNTR
Q1 25/2623 Nov 2025 - FY25 revenue up 8% YoY; Q4 recovery and expansions set stage for growth in FY26.DEEPAKNTR
Q4 24/2520 Nov 2025 - Sequential margin gains and project commissioning set the stage for growth despite tariff headwinds.DEEPAKNTR
Q2 202614 Nov 2025